Want to see SPRB full AI Analyst Report?
SPRB Stock Chart & Stats
$63.40
-$1.91(-4.25%)
At close: 4:00 PM EDT
$63.40
-$1.91(-4.25%)
Day’s Range― - ―
52-Week Range$38.06 - $159.41
Previous CloseN/A
Volume106.73K
Average Volume (3M)91.25K
Market Cap
$113.95M
Enterprise Value$42.66M
Total Cash (Recent Filing)$96.30M
Total Debt (Recent Filing)$7.67M
Price to Earnings (P/E)―
Beta-10.77
Next Earnings
Nov 16, 2026EPS Estimate
-5.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-40.87
Shares Outstanding2,874,013
10 Day Avg. Volume81,252
30 Day Avg. Volume91,253
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$154.60Price Target Upside143.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-26.93
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Balance-Sheet LeverageVery modest leverage limits debt-service pressure and preserves financial flexibility while Spruce advances its clinical programs. Compared with a highly indebted biotech, the company has less exposure to refinancing strain and may retain more options for funding development and partnerships.
Improving Free Cash Flow TrendThe improvement in free cash flow growth suggests cash consumption may be moderating relative to the prior period. Although Spruce still burns cash, a less negative trajectory could extend financial flexibility and make future capital allocation more manageable if the trend continues.
Experienced Rare-Disease LeadershipHiring a senior executive with rare-disease development, pharmacovigilance, medical-affairs, and launch experience strengthens clinical and regulatory execution. That expertise is relevant to Spruce’s specialized pipeline and could improve its ability to advance programs and pursue partnering opportunities.
Bears Say
No Current RevenueThe absence of current revenue means Spruce has no disclosed recurring product sales to support operations or validate commercial demand. Funding therefore depends on future clinical progress, partnerships, or capital raising, leaving the business model structurally dependent on development success.
Persistent Net LossesLarge and persistent losses show that Spruce remains far from self-funded profitability. Continued deficits can erode equity over time and require additional financing, while the lack of meaningful improvement in losses limits evidence that operating leverage will emerge soon.
Sustained Cash BurnOngoing negative operating and free cash flow indicates that core activities consume substantial cash rather than generating it. This constrains the resources available for clinical development and increases reliance on external financing or collaboration proceeds over the coming quarters.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $38.06 and its highest was $159.41 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $113.95M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 27 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Aug 12, 2026. The company reported -$6.68 earnings per share for the quarter, missing the consensus estimate of -$5.79 by -$0.89.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -5.68.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 2,874,013 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$6.68 in its last earnings report, missing expectations of -$5.79. Following the earnings report the stock price went up 1.422%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.60 (143.85% Upside)
$154.60 (143.85% Upside)
Blogger Sentiment
Neutral
SPRB Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.68%
12-Months-Change
Fundamentals
Return on Equity
-123.53%
Trailing 12-Months
Asset Growth
371.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
SPRB Stock 12 Month Forecast
Average Price Target
$154.60
▲(143.85% Upside)
Technical Analysis
Ownership Overview
1.00% Insiders
0.99% Mutual Funds
37.30% Other Institutional Investors
51.83% Public Companies and
Individual Investors